MiMedx (NSDQ:MDXG) said today that it it named Timothy Wright as its new chief exec, effective May 13.
Wright will replace David Coles, who has served as the interim CEO since last July, the Marietta, Ga.-based company said. MiMedx said that Wright has more than 30 years of experience in pharma, medtech and biotech.
Prior to joining MiMedx, Wright served as prez & CEO of M2Gen. Wright has also held executive positions with Teva Pharma, was the founding partner of The Ohio State University Comprehensive Cancer Drug Development Institute and acted as chair and interim CEO of Curaxis Pharma.
“Tim has been instrumental in building, transforming and strategically positioning organizations, driving them for growth and profitability across many diverse and highly competitive markets. He has extensive experience in identifying and capturing market opportunities; mobilizing multidisciplinary teams to achieve improved financial results; driving products from conception through commercialization; securing regulatory and reimbursement approvals; and negotiating complex transactions, partnerships and ventures that propel organizational growth and market share expansion. MiMedx conducted an extensive CEO search process with the assistance of an executive search firm, through which the board interviewed a number of highly qualified candidates. I am confident Tim is the right person to lead MiMedx forward on a trajectory of ethical and sustained growth. On behalf of the board, I want to thank David Coles for his service and dedication to MiMedx as interim CEO. The last ten months have been a challenging time for the company, and we greatly appreciate the leadership David has provided during this critical period,” chair Charles Evans said in a prepared statement.
“I am honored and excited to join MiMedx and lead the company forward into the next stage of its evolution. I have diligently reviewed the strength of the scientific foundation of the MiMedx business, the clinical and economic efficacy of the company’s products, the soundness of the company’s strategic plans, and the current and future market opportunities available to MiMedx. I believe strongly in the company’s potential to positively impact the lives of patients, and look forward to working with the board and management team to guide MiMedx so that it can reach its full potential while creating long-term shareholder value,” Wright said in a press release.
Capsule Tech taps Goel as chief exec
Capsule Tech, formerly Qualcomm‘s (NASDAQ:QCOM) medical-device focused subsidiary Qualcomm Life, said this week that it appointed Hemant Goel as its new CEO.
Prior to joining Andover, Mass.-based Capsule Tech, Goel served as prez of communication tech company Spok. Goel has also held positions with Siemens’ clinical solutions business, the company said.
“Hemant is very experienced at running global healthcare information technology companies, and he brings deep market knowledge, customer relationships, product, strategy, and technical expertise to his role as CEO of Capsule,” Capsule Tech owner Francisco Partners partner Chris Adams said in a prepared statement.
“We are very pleased to have Hemant on board and look forward to leveraging his industry expertise to drive continued growth and innovation,” Francisco Partners VP Justin Chen said in a press release.
“I am very excited for the opportunity to lead this exceptional organization of dedicated and talented professionals. Capsule’s solutions have a daily impact on patient care around the world, and I am honored to drive the development and execution of our strategy going forward,” Goel said in prepared remarks.
Cerebrotech appoints former Xtant CEO O’Connell as chief exec
Cerebrotech Medical Systems said yesterday that it tapped former Xtant Medical (NYSE:XTNT) CEO Carl O’Connell as its new chief executive officer.
Before he moved to Pleasanton, Calif.-based Cerebrotech, O’Connell served as prez & CEO of Xtant Medical. He has also held positions with Wright Medical, Stryker and Carl Zeiss Surgical, and acted as an advisor to GE Healthcare, Cerebrotech said.
Cerebrotech said that it also added JenaValve head John Kilcoyne to its board of directors.
“Carl and John both bring proven track records of success in the neurosurgery medical device market and we are excited to welcome them. As Cerebrotech transitions from the R&D phase to commercial expansion, the leadership and industry vision of both Carl and John will be critical for successfully shaping our future,” exec chair Martin Dieck said in a press release.
Mixed-reality cardiac ablation tech developer Sentiar said yesterday it appointed Berk Tas as its new prez and CEO.
Before joining St. Louis-based Sentiar, Tas led the development of a novel transaortic valve replacement tech through to CE Mark studies at HLT Medical, and has held various leadership roles with Sunshine Heart and Boston Scientific.
“I’m honored and excited by the opportunity to lead the team at SentiAR. I believe SentiAR’s breakthrough technology will transform the healthcare industry. 33 million people around the globe are affected by atrial fibrillation and the current cardiac ablation procedure reaches only 2% of the population. I’m motivated by SentiAR’s objective to reduce the complexity of the procedure in order to democratize access to it and ultimately, save more lives,” Tas said in a press release.
Sentiar is developing a 3D augmented reality platform that provides real-time holographic visualization of a patient’s anatomy floating over the patient to improve treatment and analysis of cardiac arrhythmias in an interventional catheter lab environment. The company said it is hopeful for an FDA submission this year.
“We’re delighted to have Berk join our leadership team. He has an impressive background in engineering and domain expertise in both cardiac electrophysiology and structural heart. Berk has a proven track record at both large organizations and startups and his entrepreneurial spirit will help take SentiAR through the next phase of growth,” chief medical officer & co-founder Dr. Jennifer Silva said in a prepared statement.
Factory-CRO names Hornyak as prez, CEO
Contract research org Factory-CRO said this week that it tapped Sapna Hornyak as its new president & CEO and named Nick Thornton as its board chair.
The Netherlands-based company said that Hornyak joins from a top 10 contract research organization and has more than 20 years of leadership experience in clinical research and medical device development.
“We are very fortunate to have a person of Sapna’s caliber leading the organization. Factory-CRO Group is at a critical growth point globally. The combination of these organizations now brings scale with a seamless global reach that we will continue to expand upon,” Thornton said in a press release.
“After many years helping companies drive device development, I am excited to contribute my experience to advance our company’s strategic objective. With our strong focus on cardiovascular, orthopedic, and urology product development amongst others, Factory-CRO Group has the focus, expertise, and global regulatory experience to guide clients efficiently to product approval,” Hornyak said in a prepared statement.
